首页> 外文期刊>JAMA facial plastic surgery >Current Trends in Management of Submental LiposisA Pooled Analysis and Survey
【24h】

Current Trends in Management of Submental LiposisA Pooled Analysis and Survey

机译:泡泡性血症池汇总分析和调查管理的当前趋势

获取原文
获取原文并翻译 | 示例
           

摘要

Importance ? Since its approval by the US Food and Drug Administration for treatment of moderate to severe submental liposis in April 2015, deoxycholic acid (Kybella) has received significant media attention as a novel aesthetic treatment. Four phase 3 clinical trials have published data demonstrating the safety and efficacy of the drug compared with placebo; however, no study has juxtaposed the product with submental liposuction. Objective ? To evaluate the efficacy of injectable deoxycholic acid in the treatment of isolated submental liposis. Evidence Review ? A pooled analysis of the data from the 2 European and 2 North American phase 3 clinical trials was performed by grouping the study participants by treatment arm to analyze efficacy, adverse effects, and treatment variables. Members of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) were also surveyed regarding their clinical use of deoxycholic acid, fees, and adverse events. Findings ? The pooled analysis included 1738 unique patients (348 men [20.0%] and 1390 women [80.0%]; mean [SD] age, 47.7 [1.6] years) and revealed that all studies demonstrated efficacy compared with placebo. However, a significant number of patients experienced pain, edema, and numbness after injection. The clinical trial population was injected with a mean (SD) of 186.0 (106.6) mg of drug per patient during the course of treatment. A total of 102 members responded to the survey, representing 4% of AAFPRS membership. Based on the results of the survey, clinicians reported charging a mean (SD) of $691.04 ($168.68) per 20-mg vial of deoxycholic acid, resulting in a cost of $6426.35 per study participant. The survey revealed a mean (SD) total cost to the patient for submental liposuction to be $2976.56 ($1041.62). Conclusions and Relevance ? Although the clinical trials demonstrated functional drug efficacy, the large volume of drug used precluded cost-effectiveness. The survey found clinical practice to differ from the protocols used in the trials. Deoxycholic acid may be only fiscally efficacious for patients with mild to moderate submental liposis who require only 20 to 30 mg of drug per treatment for 3 treatment sessions. Level of Evidence ? 1.
机译:重要性?自2015年4月批准美国食品和药物管理局治疗中度至严重泡泡病,脱氧胆酸(Kybella)已作为一种新的审美治疗得到了显着的媒体关注。四阶段3阶段临床试验已发表与安慰剂相比证明药物的安全性和功效的数据;然而,没有研究使产品与次粒性吸脂剂并置。客观的 ?评价可注射的脱氧胆酸在分离次粒性脂质治疗中的疗效。证据评论?通过将研究参与者分析治疗臂分析疗效,不良反应和治疗变量,通过将研究参与者分析来进行汇总分析。关于他们的临床使用脱氧胆酸,费用和不良事件,还调查了美国面部塑料和重建手术学院(AAFPRS学院)。发现 ?汇总分析包括1738名独特的患者(348名男性[20.0%]和1390名妇女[80.0%];意思是[SD]年龄,47.7 [1.6]年),并揭示了所有研究与安慰剂相比表现出疗效。然而,大量患者经历了疼痛,水肿和注射后麻木。在治疗过程中,每位患者的平均值(SD)注射临床试验群体为186.0(106.6)毫克药物。共有102名成员对调查作出回应,占AFFPRS成员的4%。根据调查结果,临床医生报告每20毫克甲氧胆酸的691.04美元(SD)为691.04美元(168.68美元),每项研究参与者的费用为6426.35美元。该调查显示患者患者的平均值(SD),次粒性吸脂症是2976.56美元(1041.62美元)。结论和相关性?虽然临床试验表现出功能性药物功效,但大量的药物使用绝流量效率。调查发现临床实践与试验中使用的方案不同。脱氧胆酸对于轻度至中度泡泡炎的患者可能仅适用于3种治疗季节的每次治疗中仅需要20至30mg的药物。证据水平? 1。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号